AbivaxTo Present Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology

Author: Benzinga Newsdesk | September 23, 2025 04:09pm

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

• Late Breaking Abstract titled EFFICACY OF OBEFAZIMOD IN ABTECT PHASE 3 INDUCTION TRIALS: RESULTS OF 8-WEEK THERAPY IN SUBSETS OF PATIENTS WITH AND WITHOUT PRIOR INADEQUATE RESPONSE TO ADVANCED THERAPIES to be presented Monday, October 6 at 10am CET
  
  
  
   
• Abivax management to hold an analyst and investor call on October 6 at 3pm CET / 9am ET to discuss data
  
  
  
   
• Abivax to hold symposium titled "From Evolution to Revolution: New Mechanisms in Ulcerative Colitis" on October 6 from 5:30 – 6:30pm CET
  
  
  
   

PARIS, France – September 23, 2025 – 10:05 PM CET – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company developing innovative therapies to address chronic inflammatory diseases, today announced the presentation of a late breaking abstract for its lead drug candidate, obefazimod, for the treatment of moderately to severely active ulcerative colitis (UC) at The United European Gastroenterology Congress, taking place October 4-7, 2025, in Berlin, Germany.

"The acceptance of the late-breaking abstract for presentation at UEG underscores the potential of obefazimod as a new therapeutic option for patients with ulcerative colitis," said Fabio Cataldi, MD, Chief Medical Officer of Abivax. "We are eager to share the detailed findings from our ABTECT Phase 3 induction trials, which we believe will demonstrate the efficacy of obefazimod in a diverse patient population, including those who have not responded adequately to other advanced therapies."  

Posted In: ABVX PARIS:FR